Acute Ischemic Stroke – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Acute Ischemic Stroke – Drugs In Development, 2023’, provides an overview of the Acute Ischemic Stroke pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
- The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncActicor Biotech SAS
AlaMab Therapeutics Inc
Allife Medical Science and Technology Co Ltd
AntiRadical Therapeutics LLC
APT Therapeutics Inc
AptaTargets SL
ArunA Bio Inc
Astrocyte Pharmaceuticals Inc
Athersys Inc
Avilex Pharma ApS
Basking Biosciences Inc
Bayer AG
Beijing Darwin Cell Biotechnology Co Ltd
Biogen Inc
Biosios (Beijing) Biotechnology Co Ltd
Bristol-Myers Squibb Co
Celdara Medical LLC
CervoMed Inc
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Shibeikang Biomedical Technology Co Ltd
China Resources Emde Biological Pharmaceutical Co Ltd
Clinuvel Pharmaceuticals Ltd
CSPC Pharmaceutical Group Ltd
DiaMedica Therapeutics Inc
Eight Plus One Pharmaceutical Co Ltd
Freeox Biotech SL
Genentech USA Inc
Genervon Biopharmaceuticals LLC
Glucox Biotech AB
GNT Pharma Co Ltd
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Recomgen Biotech Co Ltd
Guidon Pharmaceutics Inc
Heart Research Institute Ltd
Hibernaid Inc
Hillhurst Biopharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Ouwei Pharmaceutical Co Ltd
Jiangsu Wangao Pharmaceutical Co Ltd
Kunming Pharmaceutical Group Co Ltd
Lumosa Therapeutics Co Ltd
Meridigen Biotech Co Ltd
NC Medical Research Inc
Neurevo GmbH
Neurodawn Pharmaceutical Co Ltd
Neurophyxia BV
NeuroTrauma Sciences LLC
NoNO Inc
Novo Nordisk AS
NuvOx Pharma LLC
Oxitope Pharma BV
Pharmazz Inc
Pharming Group NV
PhytoHealth Corp
Primary Peptides Inc
Prolong Pharmaceuticals LLC
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Reliance Life Sciences Pvt Ltd
Revalesio Corp
Rubicon Biotechnology Inc
Saillant Therapeutics BV
Saneron CCEL Therapeutics Inc
Sanofi
Shanghai Braegen Pharmaceutical Co Ltd
Shanghai Hutchison Pharmaceuticals Ltd
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Wingor Biotechnology Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
Shin Poong Pharm Co Ltd
Shionogi & Co Ltd
Silver Creek Pharmaceuticals Inc
Simcere Pharmaceutical Group Ltd
SNJ Pharma Inc
Starpax Biopharma Inc
StemCyte Inc
Stream Biomedical Inc
Suzhou Auzone Biological Technology Co Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
TargED Biopharmaceuticals BV
Tasly Pharmaceutical Group Co Ltd
TheraSource LLC
Thrombolytic Science International LLC
TNAX Biopharma Corp
Translational Sciences Inc
TrueBinding Inc
Vanworld Pharmaceutical (Rugao) Company Ltd
VST Bio Corp
YouCare Pharmaceutical Group Co Ltd
Zhejiang Ausun Pharmaceutical Co Ltd
ZZ Biotech LLC